ROS1 gene fusion has become a new therapeutic target in patients with advanced or metastatic non‐small‐cell lung cancer (NSCLC) in addition to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene fusions. Here, ALK is linked to non-small cell lung carcinoma.